Drug Profile
Fananserin
Alternative Names: RP 62203Latest Information Update: 26 Jun 2002
Price :
$50
*
At a glance
- Originator Aventis
- Class Cyclic S oxides; Naphthalenes; Small molecules
- Mechanism of Action Dopamine D4 receptor antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Major depressive disorder
- Discontinued Schizophrenia
Most Recent Events
- 26 Jun 2002 No development reported - Phase-II for Anxiety disorders in France (PO)
- 26 Jun 2002 No development reported - Phase-II for Anxiety disorders in USA (PO)
- 26 Jun 2002 No development reported - Phase-II for Depression in France (PO)